Review: Newer second-line drugs for diabetes are not more cost-effective than sulfonylureas

Natalia Genere; Victor M. Montori

doi:10.7326/ACPJC-2018-168-2-008

Review: Newer second-line drugs for diabetes are not more cost-effective than sulfonylureas

Research output: Contribution to journal › Comment/debate

Original language	English
Pages (from-to)	JC8
Journal	Annals of internal medicine
Volume	168
Issue number	2
DOIs	https://doi.org/10.7326/ACPJC-2018-168-2-008
State	Published - Jan 16 2018

Access to Document

10.7326/ACPJC-2018-168-2-008

Cite this

@article{67f3679f45db45ce8f70b3e369c7d320,

title = "Review: Newer second-line drugs for diabetes are not more cost-effective than sulfonylureas",

author = "Natalia Genere and Montori, {Victor M.}",

note = "Funding Information: Sources of funding: CADTH receives funding from Canada's federal, provincial, and territorial governments, except for Quebec.",

year = "2018",

month = jan,

day = "16",

doi = "10.7326/ACPJC-2018-168-2-008",

language = "English",

volume = "168",

pages = "JC8",

journal = "Annals of internal medicine",

issn = "0003-4819",

number = "2",

}

TY - JOUR

T1 - Review

T2 - Newer second-line drugs for diabetes are not more cost-effective than sulfonylureas

AU - Genere, Natalia

AU - Montori, Victor M.

N1 - Funding Information: Sources of funding: CADTH receives funding from Canada's federal, provincial, and territorial governments, except for Quebec.

PY - 2018/1/16

Y1 - 2018/1/16

UR - http://www.scopus.com/inward/record.url?scp=85044415384&partnerID=8YFLogxK

U2 - 10.7326/ACPJC-2018-168-2-008

DO - 10.7326/ACPJC-2018-168-2-008

M3 - Comment/debate

C2 - 29335720

AN - SCOPUS:85044415384

SN - 0003-4819

VL - 168

SP - JC8

JO - Annals of internal medicine

JF - Annals of internal medicine

IS - 2

ER -

Review: Newer second-line drugs for diabetes are not more cost-effective than sulfonylureas

Access to Document

Other files and links

Cite this